Jiangxi Institute of Biological Products has secured government tender orders in Ethiopia as the Chinese antiserum maker expands overseas sales, even as its adjusted net profit fell 21.7 percent in the first half of 2026.
The company, listed in Hong Kong as Jiangxi Bio, said it won government tender orders in Ethiopia, Togo and Mongolia during the six months to June 30, marking progress in its international expansion strategy.
The value of the Ethiopia order was not disclosed. The company said its cumulative overseas contracted orders reached 6.859 million units during the period, worth approximately 27.4 million Chinese yuan.
Jiangxi Bio's international expansion is centred on Human TAT, its main product. The company sold about 9.58 million units during the first half, including 3.67 million units in overseas markets.
The company also completed market registrations or renewals in India, the Democratic Republic of the Congo, Zanzibar and Ghana during the period, adding to its presence across emerging markets.
Despite the expansion overseas, Jiangxi Bio's financial performance weakened. Revenue fell 16.5 percent year on year to approximately 83.3 million Chinese yuan, while profit for the period declined to 14.4 million Chinese yuan.
Adjusted net profit, excluding one-off items including listing expenses and tax-related adjustments, stood at 38.7 million Chinese yuan, down 21.7 percent from a year earlier.
The company attributed the decline to higher research and development costs, changes in national tax policies, lower investment income, increased depreciation and one-off listing expenses.
Jiangxi Bio increased R&D spending by 18.6 percent to approximately RMB11 million during the period, equivalent to 13.2 percent of revenue. The company said the investment was directed towards new product development and upgrades to its antiserum technology platform.
Human TAT generated approximately 77.5 million Chinese yuan in revenue, accounting for the vast majority of the company's first-half sales. Domestic sales reached about 5.91 million units, while overseas markets accounted for approximately 3.67 million units.
The company is also advancing a pipeline of antiserum products covering snakebite treatment, viral and bacterial infections and immunomodulation. Five candidate products have entered new stages of clinical development or commercialisation, according to the company.
Jiangxi Bio said it is integrating artificial intelligence and machine-learning technologies into antiserum research and manufacturing, including antigen design and antibody preparation.
The company plans to develop an integrated platform covering antigen development, equine immunisation, plasma processing and commercialisation. It said the platform is intended to reduce the cost of developing new products while allowing technologies and production capabilities to be reused across its human and veterinary pharmaceutical businesses.
